Bio-Connect

AMG-47a [882663-88-9]

Research Use Only
SYN-1007
SYNkinase
CAS Number882663-88-9
Product group Chemicals
Estimated Purity>95%
Molecular Weight535.6
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    SYNkinase
  • Product Name
    AMG-47a [882663-88-9]
  • Delivery Days Customer
    10
  • CAS Number
    882663-88-9
  • Certification
    Research Use Only
  • Estimated Purity
    >95%
  • Molecular Formula
    C29H28F3N5O2
  • Molecular Weight
    535.6
  • Scientific Description
    Chemical. CAS: 882663-88-9. Formula: C29H28F3N5O2. MW: 535.6. The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease. AMG-47 is one of two optimized chemical compounds that has been shown to be extremely effective in vivo and in vitro in inhibiting Lck as well as a number of other receptor tyrosine kinases. In an anti-CD3/ IL-2 mouse model system AMG-47 has been shown to be effective in inhibiting the Lck mediated anti-inflammatory activity (ED50 11 mg/kg; 630nM) in vivo. In multiple other in vitro assays, AMG-47 exhibits subnanomolar inhibition against Lck, and low (<10nM) inhibition against other hard to inhibit kinases such as KDR and SRC and MAPK alpha (p38alpha). Moreover at slightly higher doses but well under 10microM, AMG-47 effectively inhibits the JNK family of kinases including TYK2 at ~ 1.2microM. - The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease. AMG-47 is one of two optimized chemical compounds that has been shown to be extremely effective in vivo and in vitro in inhibiting Lck as well as a number of other receptor tyrosine kinases. In an anti-CD3/ IL-2 mouse model system AMG-47 has been shown to be effective in inhibiting the Lck mediated anti-inflammatory activity (ED50 11 mg/kg; 630nM) in vivo. In multiple other in vitro assays, AMG-47 exhibits subnanomolar inhibition against Lck, and low (< 10nM) inhibition against other hard to inhibit kinases such as KDR and SRC and MAPK alpha (p38alpha). Moreover at slightly higher doses but well under 10microM, AMG-47 effectively inhibits the JNK family of kinases including TYK2 at ~ 1.2microM.
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    51202000